Compare NCL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCL | INDP |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.5M |
| IPO Year | 2023 | 2021 |
| Metric | NCL | INDP |
|---|---|---|
| Price | $0.17 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 374.4K | 23.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.43 | 12.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,349,854.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.86 | N/A |
| 52 Week Low | $0.10 | $0.27 |
| 52 Week High | $1.47 | $13.24 |
| Indicator | NCL | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 48.88 |
| Support Level | $0.16 | $1.92 |
| Resistance Level | $0.19 | $3.19 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 22.87 | 76.80 |
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.